Fujian Aonong Biological Technology Grouporp (SHSE:603363) EBIT : ¥-3,267 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Fujian Aonong Biological Technology Grouporp EBIT?

Fujian Aonong Biological Technology Grouporp's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥-268 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-3,267 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Fujian Aonong Biological Technology Grouporp's annualized ROC % for the quarter that ended in Mar. 2024 was -7.58%. Fujian Aonong Biological Technology Grouporp's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -12.98%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Fujian Aonong Biological Technology Grouporp's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -28.47%.

Fujian Aonong Biological Technology Grouporp EBIT Historical Data

The historical data trend for Fujian Aonong Biological Technology Grouporp's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fujian Aonong Biological Technology Grouporp EBIT Chart

Fujian Aonong Biological Technology Grouporp Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

168.50

1,147.67

-1,402.81

-789.20

-3,131.64

Fujian Aonong Biological Technology Grouporp Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-132.88	-618.45	-438.86	-1,941.46	-268.16

Competitive Comparison of Fujian Aonong Biological Technology Grouporp's EBIT

For the Farm Products subindustry, Fujian Aonong Biological Technology Grouporp's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fujian Aonong Biological Technology Grouporp's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Fujian Aonong Biological Technology Grouporp's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Fujian Aonong Biological Technology Grouporp's EV-to-EBIT falls into.

Fujian Aonong Biological Technology Grouporp EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-3,267 Mil.

Fujian Aonong Biological Technology Grouporp (SHSE:603363) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Fujian Aonong Biological Technology Grouporp's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-1285.028 * ( 1 - 1.36% )	/	( (16918.018	+	16519.973)	/ 2 )
=	-1267.5516192	/	16718.9955
=	-7.58 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	13625.213	-	5277.46	-	( 212.264	-	max(0, 11359.386	-	2789.121	+	212.264	))
=	16918.018

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	12599.65	-	4816.936	-	( 207.956	-	max(0, 11125.95	-	2388.691	+	207.956	))
=	16519.973

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Fujian Aonong Biological Technology Grouporp's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1072.632	/	( ( (8444.723 + max(-3325.27, 0))	+	(8087.175 + max(-3199.117, 0)) )	/	2 )
=	-1072.632	/	( ( 8444.723	+	8087.175 )	/	2 )
=	-1072.632	/	8265.949
=	-12.98 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(647.997	+	1328.135	+	350.903)	-	(5277.46	+	0	+	374.845)
=	-3325.27

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(684.848	+	992.625	+	289.38)	-	(4816.936	+	0	+	349.034)
=	-3199.117

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Fujian Aonong Biological Technology Grouporp's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-3266.918	/	11473.474
	=	-28.47 %

Fujian Aonong Biological Technology Grouporp EBIT Related Terms

Thank you for viewing the detailed overview of Fujian Aonong Biological Technology Grouporp's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Fujian Aonong Biological Technology Grouporp (SHSE:603363) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Fujian Aonong Biological Technology Group Incorp Ltd (SHSE:603363) » Definitions » EBIT

Traded in Other Exchanges

N/A

Address

Guanyinshan Operation Center, 12th Floor, Building 10, Siming District, Fujian Province, Xiamen, CHN, 361008

Website

http://www.aonong.com.cn

Fujian Aonong Biological Technology Group Incorp Ltd is an agricultural and animal husbandry enterprise in China. The principal business activities of the company include feed-oriented service, animal protection, pig raising, and raw material trade. In addition, the company's insurance business mainly relies on the feed marketing system throughout the country to provide downstream farmers with relevant products for disease prevention and control.

Executives

Wu You Lin	Directors, senior managers
Huang Hua Dong	Director
Wen Qing Qi	Supervisors
Huang Zu Yao	Director
Lai Jun	senior management
Ye Jun Biao	Director
Yang Jing Quan	senior management
Ding Neng Shui	Director
Luo Zuo Ming	senior management
Hong Yuan Xiang	senior management
Guo Si Hu	senior management
Wu Jun	Director
Huang Ze Sen	senior management
Hou Hao Feng	senior management
Li Hai Feng	senior management

Fujian Aonong Biological Technology Grouporp (SHSE:603363) Headlines

No Headlines